CDK6 and cancer: Ali et al. synthesized and evaluated a series of 2-phenyl benzimidazole derivatives as CDK6 inhibitors, among the synthesized series compound St.35 (Table 6), observed promising results against a panel of cancer cell lines with a very high growth inhibition percentage against HL-60, NCI-H522, HCT-15, PC-3, and MCF-7 with an inhibitory percentage higher than 71%, and this compound showed dual inhibition of CDK-6 and Aurora A kinases, as well as cell cycle arrest, was observed at the G1 phase and induced total apoptosis on cancer cell line HCT-15 cells by 45.63%.